NCT07457203

Study on the Drug Interaction Between Buagafuran and Voriconazole

Clinical Study on the Drug Interaction Between Buagafuran Capsules and Voriconazole Tablets in Chinese Adult Healthy Participants

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Beijing Union Pharmaceutical Factory Ltd · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is a non-randomized, open label trial aimed at evaluating the drug interaction between Buagafuran capsules and voriconazole tablets in Chinese adult healthy participants.The research period is 7 days in total.

Detailed description

This study is a single center, non-randomized, open label trial aimed at evaluating the drug interaction between Buagafuran capsules and voriconazole tablets in Chinese adult healthy participants. The number of participants in this study is 18, and it is planned to enroll 4-6 participants for the trial first. After completing the day7 safety check, the remaining participants will enter the group. Participants are required to take a single dose of 30 mg Buagafuran on the morning of day1 and day5. Voriconazole tablets (400 mg BID) orally on day3, and voriconazole tablets (200 mg BID) orally from day4 to day6.

Conditions

• Drug Drug Interaction (DDI)

Interventions

Type	Name	Description
DRUG	Buagafuran	Buagafuran, oral administration 30mg, signal dose in the morning of day1 and day5
DRUG	Voriconazole	Voriconazole tablets, oral administration 400 mg BID on day3, and Voriconazole tablets oral administration 200 mg BID from day4 to day6.

Timeline

• Start date: 2026-04-01
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2026-03-09
• Last updated: 2026-03-09

Locations

1 site across 1 country: China